Cure My Disease

Don't miss your cure!

 Log in / Sign up

First human tests for new eczema drug halted early

NCT ID NCT05859724

Terminated Disease control Sponsor: Yellow Jersey Therapeutics AG Source: ClinicalTrials.gov ↗

Summary

This was an early-stage study to check the basic safety of a new injectable drug called NM26-2198 for people with moderate-to-severe eczema (atopic dermatitis). It involved 126 healthy volunteers and eczema patients to see how their bodies handled single and multiple doses. The main goal was to identify any side effects and see how the drug moved through the body. The study was terminated, meaning it was stopped early.

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ATOPIC DERMATITIS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Locations

  • COPERNICUS Podmiot Leczniczy Sp. z o.o., Szpital Sw. Wojciecha

    Gdansk, 80-462, Poland

  • California Clinical Trials Medical Group (CCTMG) managed by Parexel

    Glendale, California, 91206, United States

  • Centre de Recherche Saint-Louis

    Québec, G1W4R4, Canada

  • D&H Tamarac Research Center

    Tamarac, Florida, 33321, United States

  • DermEffects

    London, Ontario, N6H5L5, Canada

  • First OC Dermatology Research

    Fountain Valley, California, 92708, United States

  • Klinika Ambroziak Dermatologia

    Warsaw, 02-953, Poland

  • Paddington Testing Co.

    Philadelphia, Pennsylvania, 19103, United States

  • Panstwowy Instytut Medyczny Ministerstwa Spraw Wewnetrznych

    Warsaw, 02-507, Poland

  • Sadick Research Group

    New York, New York, 10075, United States

  • TCR Medical Corporation

    San Diego, California, 92123, United States

  • UK-SH - Lübeck

    Lübeck, Schleswig-Holstein, 23538, Germany

  • Universitätsklinikum Carl Gustav Carus

    Dresden, Saxony, 01307, Germany

  • Universitätsmedizin Mainz

    Mainz, Hesse, 55131, Germany

  • Uniwersytecki Szpital Kliniczny im. F.Chopina w Rzeszowie

    Rzeszów, 35-055, Poland

Conditions

Explore the condition pages connected to this study.

ATOPIC DERMATITIS